Sequana Medical NV announced that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented at the Heart Failure 2021 Online Congress as part of the Late Breaking Science Results were also selected for the congress’ Highlights session, held virtually on 1 July 2021. alfapump DSR is Sequana Medical’s proprietary therapy being developed for the treatment of diuretic-resistant congestion in heart failure patients. Strong results from the RED DESERT study in eight patients with diuretic-resistant heart failure were reported in May 2021, demonstrating that repeated alfapump DSR therapy could effectively replace patients’ high dose loop diuretics and restore their diuretic response and overall cardio-renal status. Details of the presentation: Title: First in Human Experience with Alfapump DSR System in Diuretic Resistant Chronic Heart Failure Presenting: Dr. Jeffrey Testani A replay of the presentation is available on demand on the congress platform. To register, click here. A copy of the presentation is available on the website of Sequana Medical.